Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Theravance, Inc. (THRX - Analyst Report) recently announced encouraging top-line data from a dose-ranging 7-day cross-over design phase IIb study (0091) on its pipeline candidate TD-4208. The randomized, double-blind, multicenter, placebo-controlled study evaluated the bronchodilatory effect, pharmacokinetics, safety and tolerability of the candidate across 6 doses (22, 44, 88, 175, 350 or 700 mcg) in patients suffering from moderate-to-severe chronic obstructive pulmonary disease (COPD).

Data from the study was highly encouraging with the candidate meeting the primary and secondary efficacy endpoints across all doses. The primary efficacy endpoint of the phase IIb study was change from baseline in trough FEV1 (forced expiratory volume in one second) at the end of the 7th day.

Data further revealed that the candidate was well tolerated by the patients across all doses. Moreover, the rates of adverse investments were observed to be identical to placebo.

Though pleased with the data on TD-4208, we believe investor focus will remain on another COPD candidate at Theravance-UMEC/VI (proposed trade name: Anoro Ellipta). The candidate, under review in the U.S., will face a panel of the U.S. Food and Drug Administration (FDA) later this month. A decision from the U.S. regulatory body on UMEC/VI’s new drug application is expected by Dec 18, 2013 (target date). Theravance has co-developed Anoro with GlaxoSmithKline (GSK - Analyst Report).

In May 2013, Theravance received a boost when the FDA approved Breo Ellipta, also co-developed with Glaxo, as a long-term maintenance therapy of airflow obstruction and for bringing down exacerbations in patients suffering from COPD. Breo Ellipta is expected to be available from the third/fourth quarter of 2013. We are positive on Theravance’s pipeline programs in collaboration with Glaxo.

Theravance, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Companies like Gilead Sciences Inc. (GILD - Analyst Report) and Actelion Ltd. (ALIOF) look more attractive in the biopharma space. Both the stocks carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%